African countries commit to ending all forms of polio at regional meeting

Brazzaville – Governments from the World Health Organization (WHO) African Region have committed to ending all remaining forms of polio and presented a scorecard to track progress towards the eradication of the virus. The commitments came at a dedicated meeting on polio at the Seventy-first WHO Regional Committee for Africa.

While the African Region was certified free of wild poliovirus one year ago following four years without a case, outbreaks of circulating vaccine-derived poliovirus (cVDPV) continue to spread. cVDPVs occur in communities where not enough children have received the polio vaccine. Cases increased last year in part because of disruptions to polio vaccination campaigns caused by COVID-19. Since 2018, 23 countries in the region have experienced outbreaks and more than half of the global 1071 cVDPV cases were recorded in Africa.

“As Chair of the African Union, I am determined to work with other countries to protect the gains of our monumental efforts against polio and finish the job against all forms of this disease in Africa. Only then, we will be able to say we delivered on our promise of a safer, healthier future for all our children,” said H.E. Félix Tshisekedi, President of the Democratic Republic of the Congo.

At the Regional Committee, countries discussed how they will begin implementing the new Global Polio Eradication Initiative (GPEI) 2022-2026 Strategy that was launched in June to urgently stop the spread of cVDPVs. The tools and tactics outlined in the Strategy to stop outbreaks include:

• Improving the speed and quality of outbreak response, including through the rapid deployment of surge staff from the WHO Regional Office for Africa to support countries as soon as outbreaks are detected.

• Further integrating polio campaigns with the delivery of essential health services and routine immunization to reach children who have never been vaccinated, help build trust with communities and improve uptake of the polio vaccine.

• Broadening the rollout of the novel oral polio vaccine type 2 (nOPV2), a new tool that could more sustainably end outbreaks of type 2 cVDPV, which are the most prevalent. To date, six countries in Africa have rolled out the vaccine with close to 40 million children vaccinated and no concerns noted for safety.

“The poliovirus disregards and defies borders. Its presence anywhere in our region is a threat to all countries. Togo is committed to working with our regional partners and acting with the urgency required to implement high quality polio campaigns and protect children across Africa. With collective action, we will defeat all forms of polio,” said Hon Professor Moustafa Mijiyawa, Togo’s Minister of Health and Public Hygiene and Universal Access to Health Care and the Chairperson of the Seventy-first session of the Regional Committee for Africa.

The scorecard presented at the Regional Committee will track indicators for implementation of timely, high-quality polio outbreak response, readiness to introduce nOPV2 as the new vaccine becomes eligible for broader use, strengthening routine immunization to close immunity gaps, and transitioning polio assets into national health systems in a strategic, phased approach. Ministers committed to regularly reviewing progress together on each of these indicators to ensure collective success in urgently finishing the job on polio and securing a polio-free future for every child across the region.

“Our success in ending wild poliovirus in the region shows what is possible when we work together with urgency. COVID-19 has threatened this triumph as governments worked hard to limit the spread of COVID-19, pausing some campaigns. However, we cannot waver, and with renewed vigour we can overcome the final hurdles that jeopardize our success. We have the know-how, but it must be backed by committed resources to reach all under-vaccinated communities and ensure that all children thrive in a world free of polio. Together, we can help the world achieve polio eradication,” said Dr Matshidiso Moeti, WHO Regional Director for Africa.

Almost 100 million African children have been vaccinated against polio since July 2020, after activities were paused due to the COVID-19 pandemic.

The Regional Committee also discussed how to accelerate the transition of polio infrastructure into countries’ health systems, so that it can continue to support immunization and disease surveillance once polio is eradicated. The polio programme has a history of supporting the response to emerging health threats in the Region, including Ebola and COVID-19, and half of polio surge staff are currently helping countries with COVID-19 surveillance, contact tracing and community engagement.

“We need increased political and financial commitment by governments and partners to walk the last mile towards ending all forms of polio,” said Dr Tunji Funsho, chair of Rotary’s National PolioPlus Committee, Nigeria. “We must reach more children faster and comprehensively to not only curb outbreaks swiftly, but to also scale up vaccination coverage and give children lasting protection against this preventable disease.”

Dr Moeti spoke during a virtual press conference today facilitated by APO Group. She was joined by Hon Professor Moustafa Mijiyawa and Dr Tunji Funsho. Also on hand to respond to questions were Dr Pascal Mkanda, Coordinator, Polio Eradication Programme, WHO Regional Office for Africa; Dr Richard Mihigo, Coordinator, Immunization and Vaccines Development Programme, WHO Regional Office for Africa; and Dr Thierno Balde, Team Leader, Operational Partnerships, WHO Regional Office for Africa.

Note to editors:

The WHO Regional Committee for Africa is the World Health Organization’s decision-making body on health policy in the African Region. It comprises of Ministers of Health or their representatives from each of the 47 Member States in the African Region.

The Global Polio Eradication Initiative is a public-private partnership led by national governments with six core partners – the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC), UNICEF, the Bill & Melinda Gates Foundation and Gavi, the Vaccine Alliance.

For Additional Information or to Request Interviews, Please Contact:

Collins Boakye-Agyemang

Communications and marketing officer

Tel: + 242 06 520 65 65 (WhatsApp)

Email: boakyeagyemangc@who.int

Ben Winkel

Director, Communications, Global Health Strategies

Email: bwinkel@globalhealthstrategies.com

Tel: +1 323 382 2290

Source: World Health Organization

WHO Says COVID-19 Wave ‘Stabilizing’ in Africa

A World Health Organization official said Thursday that the third wave of the COVID-19 pandemic on the continent appeared to be stabilizing, but numbers of infections are still very high, with almost 248,000 new cases reported in the past week alone.

During a virtual briefing on the status of the pandemic in Africa, WHO Africa Regional Director Matshidiso Moeti said that 24 countries were seeing a resurgence of infections and that deaths were rising in eight countries.

She said, “This is a preventable tragedy if African countries can get fair access to the vaccines.”

Moeti said the good news was that 13 million doses of COVID-19 vaccines were administered in the past week, triple that of the previous week. She said many of the doses came from donations and sharing arrangements through the WHO-administered COVAX vaccine cooperative.

She said 117 million doses were due to arrive in Africa in the coming month. But to meet the goal of having at least 10 percent of the continent vaccinated by the end of September, she said, another 34 million doses will be needed.

The WHO Africa director urged nations with ample supplies to keep sharing doses. She said, “With international solidarity we can protect those at highest risk of COVID-19 in all countries in the world.”

She also encouraged African governments to ensure that staffing and financial resources were available when shots arrived “to get vaccines into the arms of our populations. No precious doses should be wasted.”

Source: Voice of America

Micro Insurance Company and Lofte Kesho Are Partnering to Offer Digital Solutions to Livestock Farmers

NEW YORK, Aug. 25, 2021 (GLOBE NEWSWIRE) — Micro Insurance Company (MIC) and Lofte Kesho are partnering to offer digital solutions to livestock farmers in an effort to improve their economic well-being. Lofte Kesho, an integrated FinTech and AgriTech player, was created to help farmers collateralize animals as assets for financial benefits such as loans, working capital, cow replacement loans, and investment loans. They have also created unique systems for animal identification as well as the process of tokenizing animals using blockchain.

Lofte Kesho is partnering with Micro Insurance Company in an effort to strengthen their mission of helping farmers to unlock the financial benefits associated with their livestock. By partnering with MIC, farmers will now be able to insure their livestock, which gives them access to credit opportunities – as they will now be able to use their insured livestock as collateral. This will help improve the financial state for many farmers. Furthermore, MIC is also offering a life and hospitalization cover to the middle and low segment Livestock farmers to safeguard them against many of the risks they face, so when the unexpected happens, they are able to bounce back swiftly.

Ms. Wairimu Njoki, Country Manager, Micro Insurance Company, says:

“We are pleased to be partnering with Lofte Kesho as they improve the inclusivity of livestock farmers for enhanced access to financial solutions. Farmers have always held assets through their livestock but are often locked out of financial access because historically, financial institutions have not considered livestock as a good form of security. By MIC insuring farmers’ livestock, it has enabled financial institutions to get on board with accepting livestock as a secure asset, and thus, feel confident in accepting it as collateral.”

Bernard Njathi, Co-Founder of Lofte Kesho, says:

“Our farmers are faced with multiple challenges. According to the World Bank, by the year 2050, food demand will increase by 70%. So what does this really mean? We need to support our farmers – both our Crop and Livestock farmers. This is why Lofte Kesho Kenya Limited acknowledges that our livestock farmers are not necessarily poor but lack a supportive ecosystem that properly promotes and unlocks animal identification, valuation, insurance and animal collateralized loans. As a result, Lofte Kesho is excited to partner with Micro Insurance Company to further our aim of providing value-added services to livestock farmers in the areas of animal health, nutrition, and productivity. Our partnership with MIC will further enhance our ability to offer peace of mind to livestock farmers.”

MIC and Lofte Kesho join forces to address both the financial and insurance inclusivity against the marginalized – using the FarmTrek platform as a route to access these services. This partnership combines Lofte Kesho’s knowledge of livestock along with MIC’s expertise in product design to ensure optimal product consideration and adjusted premiums.

About Lofte Kesho

Founded in 2018 with headquarters in Kenya, Lofte Kesho is an integrated FinTech and AgriTech player offering an animal identification and traceability platform. In partnership with InfoCorp Technologies, Lofte Kesho has rolled out FarmTrek, a solution that brings inclusive financial services to the livestock industry in emerging markets via its blockchain-based platform. Lofte Kesho works with smallholder farmers to unlock financial benefits associated with their animals.

For more information, please contact Bernard.Njathi@loftekesho.com or visit: https://www.loftekesho.com/

About Micro Insurance Company

Micro Insurance Company (MIC) is a global insurance platform delivering technology, underwriting, policy management, and distribution. MIC provides insurance to platforms, micro & small businesses, and to the 4 billion people on the planet that are currently unserved. Whereas most insurtechs seek to improve existing monoline products and markets, we follow the concept of straight through processing. We do this in order to create highly relevant insurance products that we can offer globally at a very low cost via our platform to support people in their local communities. Micro Insurance Company is the world’s first global end-to-end digital microinsurance platform that combines reinsurance capacity, in-country insurance licenses, world class distribution, and market leading AI functionality.

For more information, please contact wairimu.njoki@microinsurance.com or visit: https://microinsurance.com/

Customertimes Announces Expanded Salesforce Industries Focus

NEW YORK, Aug. 25, 2021 /PRNewswire/ — Customertimes is announcing an expanded focus on its Salesforce Industries practice throughout EMEA and North America.

With the acquisition of Vlocity in 2020, Salesforce continues its push into industry vertical solutions. Customertimes is a Salesforce Master Navigator, and with deep experience across all Salesforce Industry clouds, it is well-positioned to deliver outstanding business results for any industry project.

Internationally recognized for its strong Salesforce partnership, this practice expansion will allow Customertimes to continue to deliver true digital transformation for complex verticals like Financial Services, Healthcare & Life Sciences, Comms & Media, and Utilities.

“Currently, the industry is experiencing a huge gap in Vlocity skills,” says Rinoy Varkey, Practice Head & SVP Salesforce Industries (Vlocity) at Customertimes. “We are here to fill that gap. We have the right people in place at the right time – our 800+ certified global Salesforce consultants can handle any project from the ground up or help with staff augmentation on existing projects.”

“With more than 1400 Salesforce certifications and leading Salesforce Industries Cloud experts on our team, we are known for our value-driven service offerings and efficient program delivery,” adds Adriano Acciaroli, VP EMEA at Customertimes. “We have engagement models that suit any region or customer segment with uncompromising quality and support.”

Key areas of engagement currently include Enterprise Product Modelling, Enterprise Product Catalog Development/Configuration, CPQ Technical Architecture, CPQ Development/Configuration, and OmniStudio Consultation/Development.

To learn more:

About Customertimes 
Customertimes Corp. is a global consulting and software firm dedicated to making the top IT technologies accessible to customers. With more than 4000 projects completed and 1300+ highly skilled experts, their solutions are engineered to help clients realize true business transformation and achieve maximum value from their technology investments. An early entrant into the Salesforce consulting and implementation space in Eastern Europe and an award-winning product development organization, Customertimes Corp. currently has headquarters in New York City, along with regional offices in London, Paris, Toronto, Kyiv, Minsk, Riga, and Moscow. For more information, visit www.customertimes.com.

Media Contact:
Meriel Sikora
Customertimes
212-520-0059
meriel.sikora@customertimes.com

GenScript Biotech annonce ses résultats du premier semestre 2021

L’entreprise affiche une croissance explosive de l’activité d’organisation de développement et de fabrication sous contrat (CDMO) de thérapie génique et cellulaire (GCT) et des investissements stratégiques en thérapie génique et cellulaire

NANJING, Chine, 25 août 2021 /PRNewswire/ — GenScript Biotech Corporation (HKEX: 1548.HK) (GenScript) a publié aujourd’hui ses résultats financiers du premier semestre 2021 pour le semestre clos le 30 juin. Le Groupe a également annoncé avoir étendu sa présence dans l’industrie de la thérapie génique et cellulaire grâce à des investissements massifs.

Au cours du premier semestre 2021, le Groupe a maintenu une forte dynamique dans tous les secteurs d’activité. Le chiffre d’affaires total a augmenté de 38 % pour atteindre 229,6 millions de dollars et la marge brute a augmenté de 28,1 % pour atteindre 138,6 millions de dollars.

Le chiffre d’affaires de l’activité de thérapie non cellulaire du Groupe a augmenté de 36,6 % pour atteindre 195,7 millions de dollars, avec un bénéfice brut de 104,7 millions de dollars, soit une augmentation de 23,0 % en glissement annuel, y compris la percée historique de son activité de développement et de fabrication sous contrat de thérapies géniques et cellulaires dans la croissance explosive du chiffre d’affaires. Ce résultat s’appuie sur les premiers investissements du Groupe dans ce domaine et sur ses avantages en matière de solutions de R&D et de fabrication de plasmides et lentivirus. En ce qui concerne l’activité de thérapie cellulaire du Groupe, le chiffre d’affaires a augmenté de 46,8 % sur un an pour atteindre 33,9 millions de dollars, grâce à la reconnaissance continue de ses succès et à des investissements importants.

En tant que fournisseur de synthèse génique numéro un dans le monde, GenScript a établi une base technique solide pour ses activités de thérapie génique et cellulaire. Tandis que les activités de GenScript dans le domaine des services et des produits des sciences de la vie, le développement de contrats biologiques et l’organisation de la fabrication, et les activités de thérapie cellulaire sont toutes en train d’atteindre une forte dynamique, le Groupe étend sa présence à travers la chaîne de valeur de la thérapie génique et cellulaire en investissement de façon intensive.

Au cours du premier semestre 2021, les dépenses de R&D ont augmenté de 51,6 % en glissement annuel pour atteindre 175,1 millions de dollars. L’entreprise de thérapie non cellulaire a investi environ 10 % de son chiffre d’affaires dans la construction d’installations de bonnes pratiques de fabrication et dans d’autres extensions d’infrastructures. L’activité de thérapie cellulaire a dépensé 154,5 millions de dollars en R&D, une augmentation de 52,1 % par rapport à l’année précédente, avec une concentration des investissements sur les études cliniques de cilta-cel et les installations de fabrication qui soutiennent les essais cliniques en cours et la commercialisation future de l’entreprise.

GenScript est en train d’inaugurer l’essor de la thérapie génique et cellulaire comme la prochaine révolution de l’industrie bio-technologique, en exploitant l’énorme potentiel des organisations de recherche contractuelle et des plateformes de développement et de fabrication contractuelles. Au cours des deux à trois prochaines années, l’entreprise de sciences de la vie et l’entreprise de développement et de fabrication de produits biologiques augmenteront leurs investissements stratégiques dans ce domaine. Cela comprend des investissements dans les services liés à la thérapie génique et cellulaire, l’utilisation de la technologie d’automatisation pour moderniser les lignes de production, et l’accélération du lancement des produits de thérapie cellulaire en cours et de la R&D dans les nouveaux pipelines.

Etan Hon Named Product Manager of Turbo Aftermarket Services for Nikkiso Cryogenic Services

TEMECULA, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (Group), a subsidiary of Nikkiso Co., Ltd (Japan), is pleased to announce that Etan Hon has been appointed Product Manager of Turbo Aftermarket Services (AMS) for the Nikkiso Cryogenic Services unit (NCS).

This addition to their management team supports the Group’s objectives to further grow their AMS for Turboexpanders. The Turbo All Brands line will also expand to support and service more brands, including ACD, Rotoflow, Atlas Copco, and Cryostar among others.

Etan received a degree in Aerospace engineering from the University of California, San Diego. He started his career by providing oilfield services to customers within the oil & gas industry in Texas working for Schlumberger and Baker Hughes. In 2017, he joined ACD LLC as a Field Service Manager. After the acquisition by Nikkiso in 2019, he transitioned into the role of Service Manager of Turbo AMS for NCS and helped move the ACD Turbo AMS division into a new facility in Irvine, CA. He helped re-develop the standards and processes with the international service centers for the Turbo AMS in Irvine. The new structure has created a successful operating business locally and will ensure proper support to the Turbo AMS team globally.

“The NCS team is excited to have Etan in this new Turbo AMS Product Management role,” according to Jim Estes, President of NCS. “His years of experience and focus on customer service has exceeded our expectations. I’m looking forward to his success continuing in this new role.”

Nikkiso Cryogenic Services provides service and support globally, including locations in Malaysia, Germany, India, Australia, Taiwan and China as well as six locations in North America.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly-controlled group of approximately 20 operating entities.

For more information please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:

Anna Quigley
+1.951.383.3314
aquigley@cryoind.com